Equipment and Services Health Care Equipment and Supplies

  • PARIS, Dec 13- Artificial heart-maker Carmat is' rather confident' on the resumption of implants in the final-stage clinical trial for its artificial hearts, its chief executive Stephane Piat said on Tuesday. France's national drugs agency, ANSM, ordered Carmat to suspend further implants earlier this month following the death of a patient in October.

  • PARIS, Dec 13- Artificial heart-maker Carmat is' rather confident' on the resumption of implants in the final-stage clinical trial for its artificial hearts, its chief executive Stephane Piat said on Tuesday. France's national drugs agency, ANSM, ordered Carmat to suspend further implants earlier this month following the death of a patient in October.

  • Stryker CEO: Medical tax is a 'job and innovation killer'

    Kevin Lobo, Stryker chairman & CEO, talks about some of the company's newest technology in hard tissue robotics and why reform is needed in Obamacare.

  • WARSAW, Indiana/ WASHINGTON, Dec 9- When Donald Trump takes over as president on Jan. 20, one of the first business tax breaks he delivers is likely to go to the U.S. medical device industry and companies like Mark Throdahl's. The chief executive of OrthoPediatrics Corp, based in northern Indiana, said his company has been able to hire more workers since the temporary...

  • Although legal experts think J&J faces an uphill battle, both they and investors believe the Texas jury's penalty, the largest product liability verdict so far this year, is unlikely to stand. It is the second large verdict against J&J in the Pinnacle implant litigation, which has been consolidated before U.S. District Court Judge Edward Kinkeade in Texas.

  • Dec 2- A federal appeals court on Friday threw out an antitrust verdict that ordered medical device maker Becton Dickinson and Co to pay rival Retractable Technologies Inc $340 million in damages over its marketing of safety syringes. The 5th U.S. Circuit Court of Appeals in New Orleans called Retractable's claim that Becton violated the Sherman Act by trying...

  • PARIS, Dec 1- Shares in artificial heart maker Carmat fell more than 13 percent on Thursday after France's national drugs agency ordered it to suspend further implants in a second test phase following the death of a patient in October. Carmat shares were down by 13.19 percent at 29.01 euros in end-session trading, wiping some 26 million euros off the company's...

  • PARIS, Dec 1- Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October. Carmat shares were down by 12.4 percent at 29.55 euros in mid-session trading, wiping some 26 million euros off the company's stock market value.

  • PARIS, Dec 1- Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October. Carmat shares were down by 18.5 percent at 27.50 euros in morning trading, with around 40 million euros wiped off its stock market value. Carmat Chief Executive...

  • PARIS, Nov 30- France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October. A spokeswoman for the drugs agency said that it had requested further information from the company following the patient's death, which was first reported by Europe 1 radio.

  • Revenue at Medtronic's diabetes unit rose 3 percent to $462 million in the second quarter ended Oct. 28. MiniMed 670 G- the first device that allows a glucose sensor to communicate with an insulin pump and automatically regulate insulin flow- was approved by the U.S. Food and Drug Administration in September and is expected to launch in spring 2017..

  • *Qtrly revenue $7.35 bln vs. est. Sales in its cardiac and vascular unit, where Medtronic sells defibrillators, pacemakers, heart valves and stents, were $2.58 billion in the second quarter ended Oct. 28, below analysts' average estimate of $2.64 billion, compiled by Evercore ISI. MiniMed 670 G was approved by the U.S. Food and Drug Administration in September and is...

  • Nov 22- Medtronic Plc, the world's largest standalone medical device maker, reported a 4 percent rise in quarterly revenue, helped by higher demand for its minimally invasive devices and heart products. The company's net income rose to $1.11 billion, or 80 cents per share, in the second quarter ended Oct. 28 from $520 million, or 36 cents per share, a year earlier.

  • *Kenya, Ghana attract insurers, markets still modest. NAIROBI, Oct 31- Families gather at Nairobi's Garden Square restaurant each evening seeking donations from friends and relatives to meet spiralling medical, school and funeral costs. Changing attitudes and rising disposable incomes in many parts of Africa, from Kenya in the east to Ghana in the west, are...

  • Oct 28- Medical device maker St. Jude Medical Inc said on Friday it has notified doctors to stop implants of one of its cardiac pacemakers, citing reports of problems with electronic data reporting caused by a battery malfunction that could put patients at risk. Jude Chief Medical Officer Mark Carlson said in a statement, adding that the company remains...

  • The company reported a net profit of $228 million, or 17 cents per share, in the third quarter ended Sept. 30. That compared with a loss of $198 million, or 15 cents per share, a year earlier, largely due to litigation charges. Net sales rose to $2.11 billion from $1.89 billion.

  • Oct 25- Edwards Lifesciences Corp on Tuesday reported third quarter sales of its minimally invasive heart valve replacements that fell short of Wall Street estimates, and its previously high-flying shares plunged more than 14 percent. Global transcatheter heart valve therapy sales jumped 38.5 percent to $410.1 million, missing analysts' consensus...

  • Oct 25- Edwards Lifesciences Corp on Tuesday reported third quarter sales of its critically important minimally invasive heart valve replacements that fell short of Wall Street estimates, and its previously high-flying shares plunged nearly 20 percent. Edwards shares, which had been up about 44 percent year-to-date, making it one of the best performers in...

  • FDA STATEMENT ADVISES PATIENTS WITH ST JUDE HEART IMPLANTS TO CONTINUE TO USE DEVICES AS DIRECTED BY DOCTORS.

  • FDA SAYS CONTINUES TO' THOROUGHLY ACCESS' ALL CLAIMS OF CYBER VULNERABILITIES IN ST JUDE MEDICAL HEART DEVICES.